Cyclooxygenase-2--specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients.
about
Antiplatelet agents and anticoagulants for hypertensionRofecoxib for rheumatoid arthritisRofecoxib for osteoarthritisAntiplatelet agents and anticoagulants for hypertensionNSAIDs: gastroprotection or selective COX-2 inhibitor?Cardiovascular and gastrointestinal effects of COX-2 inhibitors and NSAIDs: achieving a balanceCyclooxygenase inhibition: between the devil and the deep blue seaCardiovascular hazard of selective COX-2 inhibitors: myth or reality?Antithrombotic therapy in hypertension: a Cochrane Systematic reviewNonsteroidal Anti-Inflammatory Drugs and the KidneyOpposite effects of cyclooxygenase-1 and -2 activity on the pressor response to angiotensin IIThe role of cyclooxygenase-2 in cell proliferation and cell death in human malignancies.Renal function during rofecoxib therapy in patients with metastatic cancer: retrospective analysis of a prospective phase II trial.Rheumatology and musculoskeletal medicineRenal medullary cyclooxygenase-2 and (pro)renin receptor expression during angiotensin II-dependent hypertension.Lumiracoxib: the evidence of its clinical impact on the treatment of osteoarthritis.Therapeutic potential of COX-2 inhibitors in arthritis.COX-2 inhibitors compared and contrasted.High blood pressure in the geriatric population: treatment considerations.Current pharmacotherapy for the treatment of severe burns.Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors.Cardiorenal Effects of Newer NSAIDs (Celecoxib) versus Classic NSAIDs (Ibuprofen) in Patients with Arthritis.Rofecoxib: an update on physicochemical, pharmaceutical, pharmacodynamic and pharmacokinetic aspects.Adverse Drug Events Involving COX-2 Inhibitors.Key questions concerning paracetamol and NSAIDs for osteoarthritis.Relationship between cyclooxygenase-2 inhibition and thrombogenesis.Cardiovascular effects of selective cyclooxygenase-2 inhibitors.Rofecoxib is a potent inhibitor of cytochrome P450 1A2: studies with tizanidine and caffeine in healthy subjects.Cardiovascular risk and COX-2 inhibition in rheumatological practice.Celecoxib and cardiovascular risks.Comparative effects of non-steroidal anti-inflammatory drugs (NSAIDs) on blood pressure in patients with hypertension.Safe pharmacologic treatment strategies for osteoarthritis pain in African Americans with hypertension, and renal and cardiac disease.Drug interactions and drugs that affect blood pressure.Minimizing risks of NSAIDs: cardiovascular, gastrointestinal and renal.Nonsteroidal anti-inflammatory drugs and the heart: what is the danger?Hypertension in rheumatoid arthritis.Review of the cardiovascular safety of COXIBs compared to NSAIDS.Adverse cardiovascular effects of NSAIDs: driven by blood pressure, or edema?Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer.Risk of stroke associated with nonsteroidal anti-inflammatory drugs
P2860
Q24234617-738C5F8E-6B86-412C-B42A-46B9B60360EBQ24244836-58D3B192-A5BB-488C-95A4-7190BAE41175Q24244871-9D0D7579-60CB-412B-A6F3-B1E93FF21BA6Q24246637-FF37E34E-E024-4B86-84C1-207A46A3F679Q28168965-3F7ABA37-E65B-4D1A-BE79-2BD60A0D486BQ28191924-0C31C73C-50A7-4913-80E7-57B16CBBA995Q28192790-F7071110-CE17-4180-A775-A46FA71B8B42Q28198746-A7A658B4-A770-4DDE-8A9F-4239016C45A3Q28213879-579AB5AD-8BED-4AA1-8404-AE154B5433D0Q28386844-EA91A8A9-0504-479F-A3BE-82189736B15DQ28508911-DF49F820-6151-40E1-886B-6561ED09375EQ33737469-C3554F9D-3FB0-49F9-9221-483C90DC8BB2Q33786234-8956D36D-9579-49F6-BECC-4F5BD7D430DBQ34098905-3B7D019C-11EC-4F05-B4EB-923D6079BF1CQ34355950-BC9CDA4A-881F-45BF-AD06-4E70043ADCACQ34449825-9BF4500B-3061-478D-83BA-AAFA449CF455Q34481579-D101641B-D903-4CB1-9B48-D658E2F0FE8BQ34515513-11F3DFB4-76FC-414E-84F0-ED090DE45236Q34714754-E5180A1C-D47E-4524-9B71-67FBD7663DE3Q35076594-BAE03EC8-5454-4B0C-A34C-0623180A19EDQ35083808-20A30698-1F7A-4C82-9DBB-6496C7931D1CQ35102135-774CB4A4-76F9-48C5-9755-8D6C8B6DCF8EQ35195182-288476A3-2A32-4CEB-A883-8F6BBEE0090DQ35201026-34D8A0CE-E4BF-4DFA-BA68-F2B6D57AB6D9Q35551913-D2640628-16FD-42AC-B3CA-492F1AF4A7AEQ35750211-2F8382C7-F2CE-4B2F-8DA0-EC1A25D65678Q35777371-738CD6F7-CFFE-4C4F-B2EF-ED283F8437B2Q35827758-16C6406A-5622-4B6A-AF01-C64D3E1CFD14Q35896154-5F4F88A6-6288-4ACB-AF19-9142561A06C4Q36299969-0C7D848A-2C85-46B5-A6DD-38697E0150C1Q36412644-E6CC813C-B348-46BC-B1DF-53D7E7BE9FE0Q36559595-3D072A42-46BD-4162-9B41-44CA0A4B3461Q36617766-DAB1B7FB-E835-4CDE-8DAF-33F270F02E51Q36673018-D16955F8-D71D-44BE-B2DC-99F678588B6CQ37133897-E1904847-B4FF-44D3-819E-5264537A1E37Q37158219-5B772178-A645-4291-AFB7-C23AF3697727Q37178937-1FBB9008-9D52-47F9-802F-8A6FF00703CAQ37362717-AF3C5FBD-B72C-4C71-A54E-A1122F122024Q37386059-59E4DFE2-26B7-4351-AF2C-B61ABBE98F73Q37464386-2EBE1A25-5A95-482B-A52E-EE7917B7B349
P2860
Cyclooxygenase-2--specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients.
description
2001 nî lūn-bûn
@nan
2001 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մարտին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Cyclooxygenase-2--specific inh ...... nsive osteoarthritis patients.
@ast
Cyclooxygenase-2--specific inh ...... nsive osteoarthritis patients.
@en
Cyclooxygenase-2--specific inh ...... nsive osteoarthritis patients.
@nl
type
label
Cyclooxygenase-2--specific inh ...... nsive osteoarthritis patients.
@ast
Cyclooxygenase-2--specific inh ...... nsive osteoarthritis patients.
@en
Cyclooxygenase-2--specific inh ...... nsive osteoarthritis patients.
@nl
prefLabel
Cyclooxygenase-2--specific inh ...... nsive osteoarthritis patients.
@ast
Cyclooxygenase-2--specific inh ...... nsive osteoarthritis patients.
@en
Cyclooxygenase-2--specific inh ...... nsive osteoarthritis patients.
@nl
P2093
P1476
Cyclooxygenase-2--specific inh ...... nsive osteoarthritis patients.
@en
P2093
D Normandin
K M Verburg
SUCCESS VI Study Group
P356
10.1097/00045391-200103000-00003
P577
2001-03-01T00:00:00Z